- Conditions
- Prostatic Neoplasm, Osteoporosis
- Interventions
- Resistance Exercise, Flexibility Training
- Behavioral
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 85,759
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dementia, Alzheimer's Disease
- Interventions
- Rasagiline
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 31
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
- Conditions
- Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Mixed Cell Adenocarcinoma, Refractory Endometrial Serous Adenocarcinoma, Refractory Endometrial Undifferentiated Carcinoma
- Interventions
- Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment, Questionnaire Administration, Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive), Progesterone Receptor Positive ( PGR Positive; PR Positive)
- Drug · Other · Diagnostic Test
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Abington, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA App, Skyn Monitor Lab Session 2
- Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Gainesville, Florida
- Conditions
- Dermatitis Atopic
- Interventions
- Amlitelimab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 42
- States / cities
- Scottsdale, Arizona • Fountain Valley, California • Fremont, California + 36 more
- Conditions
- COVID-19
- Interventions
- Aprepitant injectable emulsion, Saline Placebo
- Drug
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Sheffield, Alabama • Orange, California • New Haven, Connecticut
- Conditions
- Pediatric Hematologic Malignancies
- Interventions
- Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Epilepsy, Partial
- Interventions
- Seletracetam (ucb 44212)
- Drug
- Lead sponsor
- UCB S.A. - Pharma Sector
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • San Francisco, California • Stanford, California + 4 more
- Conditions
- Overweight, Obese
- Interventions
- Steps to Health, Steps to Health Plus!
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Alopecia Areata
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Heart Failure, Congestive, Pulmonary Disease, Chronic Obstructive, Depression, Anxiety
- Interventions
- ACCES - Adjusting to Chronic Conditions with Education and Support
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- ABT-089, Placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 23
- States / cities
- Mesa, Arizona • Lafayette, California • Oceanside, California + 20 more
- Conditions
- Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Metabolic Disease
- Interventions
- Losartan, Zileuton, N-Acetylcysteine, Pravastatin, Erythromycin
- Drug
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma, Unresectable (Stage III) Melanoma, Metastatic (Stage IV) Melanoma
- Interventions
- Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg), Omaveloxolone Capsules (10 mg/capsule), Omaveloxolone Capsules (50 mg/capsule)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 10
- States / cities
- Mobile, Alabama • Fayetteville, Arkansas • Aurora, Colorado + 7 more
- Conditions
- Healthy
- Interventions
- Mirikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Cypress, California • Daytona Beach, Florida • Miami, Florida + 2 more
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- A.1 Lucinactant, B.3 SoC, A.2 Lucinactant, A.3 Lucinactant, A.4 Lucinactant, B.1 Lucinactant, B.2 Lucinactant
- Drug · Other
- Lead sponsor
- Windtree Therapeutics
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Warrington, Pennsylvania
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
- Interventions
- D-4517.2
- Drug
- Lead sponsor
- Ashvattha Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Lemont, Illinois • Indianapolis, Indiana + 12 more
- Conditions
- Photosensitive Epilepsy
- Interventions
- Valproic Acid, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Chesterfield, Missouri • Nashville, Tennessee
- Conditions
- Pancreatic Cancer
- Interventions
- Directional Brachytherapy Source Implant
- Device
- Lead sponsor
- CivaTech Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Chicago, Illinois • Oak Lawn, Illinois + 3 more
- Conditions
- Tobacco Use Cessation
- Interventions
- Brief counseling (Ask, Advise, Arrange)
- Behavioral
- Lead sponsor
- Oregon Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- HIV Infection
- Interventions
- Placebo, Maraviroc
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 4
- States / cities
- San Francisco, California • Stanford, California • Chicago, Illinois + 1 more
- Conditions
- Oligodendroglioma, Adult
- Interventions
- Antineoplaston therapy (Atengenal + Astugenal)
- Drug
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anorexia Nervosa, Osteopenia, Osteoporosis, Eating Disorders
- Interventions
- Recombinant Human Growth Hormone, Placebo for Recombinant Human Growth Hormone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 45 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- Counseling, Dietary Counseling and Surveillance, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training
- Other · Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio